ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation?

References

• Imamura R, Ishiguro S, Shi Y et al. ABO-incompatible kidney transplantation with anti-CD20 monoclonal antibodies, intravenous immunoglobulin and plasmapheresis without splenectomy: a case report. Xenotransplantation13(2), 133–135 (2006).
   PubMed Web of Science ®Google Scholar
• Sonnenday CJ, Warren DS, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am. J. Transplant.4(8), 1315–1322 (2004).
   PubMed Web of Science ®Google Scholar
• Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl. Int.22(4), 447–454 (2009).
   PubMed Web of Science ®Google Scholar
• Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am. J. Transplant.5(1), 145–148 (2005).
   PubMed Web of Science ®Google Scholar
• Squifflet J, De Meyer M, Malaise J, Latinne D, Pirson Y, Alexandre G. Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Exp. Clin. Transplant.2(1), 208–213 (2004).
   PubMedGoogle Scholar
• Montgomery RA, Locke JE, King KE et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation87(8), 1246–1255 (2009).
   PubMed Web of Science ®Google Scholar
• Stegall M, Dean P, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am. J. Transplant.9(5), 998–1005 (2009).
   PubMed Web of Science ®Google Scholar
• Matter M, Ochsenbein A. Natural antibodies target virus–antibody complexes to organized lymphoid tissue. Autoimmun. Rev.7(6), 480–486 (2008).
   PubMed Web of Science ®Google Scholar
• Paul L, van Es L, Riviere G, Eernisse G, de Graeff J. Blood group B antigen on renal endothelium as the target for rejection in an ABO-incompatible recipient. Transplantation26(4), 268–271 (1978).
   PubMed Web of Science ®Google Scholar
• Tobian A, Shirey R, Montgomery R, Ness P, King K. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion48(11), 2453–2460 (2008).
   PubMed Web of Science ®Google Scholar
• Hume D, Merrill J, Miller B, Thorn G. Experiences with renal homotransplantation in the human: report of nine cases. J. Clin. Invest.34(2), 327–382 (1955).
   PubMed Web of Science ®Google Scholar
• Tanabe K, Takahashi K, Agishi T, Toma H, Ota K. Removal of anti-A/B antibodies for successful kidney transplantation between ABO blood type incompatible couples. Transfus. Sci.17(3), 455–462 (1996).
   PubMedGoogle Scholar
• Aeschbacher B, Wiedmer W, Stuck A, Gaenger K, Frey F, Nydegger U. [Immunoadsorption of anti-B antibodies as preparation for an ABO-incompatible kidney transplantation]. Schweiz. Med. Wochenschr.117(19), 716–722 (1987).
   PubMedGoogle Scholar
• Raja R, Bannett A, Caruana R, Baquero A. Removal of antibodies with immunoadsorption from an ABO incompatible recipient prior to renal transplant. ASAIO Trans.32(1), 102–103 (1986).
   PubMedGoogle Scholar
• Thaiss F. Specific issues in living donor kidney transplantation: ABO-incompatibility. Atheroscler. Suppl.10(5), 133–136 (2009).
   PubMed Web of Science ®Google Scholar
• Mendez R, Sakhrani L, Chaballout A, Mendez R. ABO incompatible transplants involving A2 donors. Transplant. Proc.23(2), 1738–1741 (1991).
   PubMed Web of Science ®Google Scholar
• Alexandre GP, Squifflet JP, De Bruyere M et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant. Proc.19(6), 4538–4542 (1987).
   PubMed Web of Science ®Google Scholar
• Tanabe K, Takahashi K, Sonda K et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation65(2), 224–228 (1998).
   PubMed Web of Science ®Google Scholar
• Toki D, Ishida H, Horita S, Yamaguchi Y, Tanabe K. Blood group O recipients associated with early graft deterioration in living ABO-incompatible kidney transplantation. Transplantation88(10), 1186–1193 (2009).
   PubMed Web of Science ®Google Scholar
• Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation84(12 Suppl.), S4–S7 (2007).
   PubMed Web of Science ®Google Scholar
• Mannami M, Mitsuhata N. Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil. Transplantation79(12), 1756–1758 (2005).
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol.6(5), 394–403 (2006).
   PubMed Web of Science ®Google Scholar
• Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation. Nat. Clin. Pract. Nephrol.2(4), 221–230 (2006).
   PubMedGoogle Scholar
• Kahwaji J, Tong C, Jordan S, Vo A. Rituximab: an emerging therapeutic agent for kidney transplantation. Transplant. Res. Risk Manage.1, 15–29 (2009).
   Google Scholar
• Jordan SC, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans. Am. Clin. Climatol. Assoc.117, 199–211; discussion 211 (2006).
   PubMedGoogle Scholar
• Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney transplantation. Transplantation84(12 Suppl.), S33–S36 (2007).
   PubMed Web of Science ®Google Scholar
• Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am. J. Transplant.7(2), 402–407 (2007).
   PubMed Web of Science ®Google Scholar
• Sidner R, Book B, Agarwal A, Bearden C, Vieira C, Pescovitz M. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum. Antibodies13(3), 55–62 (2004).
   PubMedGoogle Scholar
• Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum.56(9), 3044–3056 (2007).
   PubMed Web of Science ®Google Scholar
• Kopchaliiska D, Zachary A, Montgomery R, Leffell M. Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients. Transplantation87(9), 1394–1401 (2009).
   PubMed Web of Science ®Google Scholar
• Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation74(9), 1207–1210 (2002).
   PubMed Web of Science ®Google Scholar
• Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation76(4), 730–731 (2003).
   PubMed Web of Science ®Google Scholar
• Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO-incompatible kidney transplantation and rituximab. Transplant. Proc.37(8), 3286–3287 (2005).
   PubMed Web of Science ®Google Scholar
• Villicana R. ABO incompatible kidney transplantation using rituximab, pre-transplant plasmapheresis followed by high dose IVIG: a single center experience. Am. J. Transplant.9(Suppl. 2), 560 (2009).
   Google Scholar
• Genberg H, Kumlien G, Wennberg L, Tydén G. Long-term results of ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab. Transplantation84(12 Suppl.), S44–S47 (2007).
   PubMed Web of Science ®Google Scholar
• Tydén G, Donauer J, Wadström J et al. Implementation of a protocol for ABO-incompatible kidney transplantation – a three-center experience with 60 consecutive transplantations. Transplantation83(9), 1153–1155 (2007).
   PubMed Web of Science ®Google Scholar
• Wilpert J, Fischer K, Pisarski P et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol. Dial. Transplant. DOI: 10.1093/ndt/gfq229 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Toki D, Ishida H, Setoguchi K et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am. J. Transplant.9(3), 567–577 (2009).
   PubMed Web of Science ®Google Scholar
• Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib. Nephrol.162, 61–74 (2009).
   PubMed Web of Science ®Google Scholar
• Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation89(12), 1466–1470 (2010).
   PubMed Web of Science ®Google Scholar
• Segev D, Simpkins C, Warren D et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am. J. Transplant.5(10), 2570–2575 (2005).
   PubMed Web of Science ®Google Scholar
• Montgomery R, Locke J. ABO-incompatible transplantation: less may be more. Transplantation84(12 Suppl.), S8–S9 (2007).
   PubMed Web of Science ®Google Scholar
• Kahwaji J, Toyoda M, Reinsmoen N et al. Infectious complications associated with rituximab for desensitization protocols. Am. J. Transplant.10(Suppl. 4), 170 (2010).
   Google Scholar
• Reding R, Squifflet J, Latinne D, De Bruyère M, Pirson Y, Alexandre G. Early postoperative monitoring of natural anti-A and anti-B isoantibodies in ABO-incompatible living donor renal allografts. Transplant Proc.19(1 Pt 3), 1989–1990 (1987).
   PubMed Web of Science ®Google Scholar
• Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation77(4), 542–548 (2004).
   PubMed Web of Science ®Google Scholar
• Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation85(12), 1745–1754 (2008).
   PubMed Web of Science ®Google Scholar
• Oppenheimer F, Revuelta I, Serra N et al. [ABO incompatible living donor kidney transplantation: a dream come true. Experience of Hospital Clínic of Barcelona]. Nefrologia30(1), 54–63 (2010).
   PubMed Web of Science ®Google Scholar
• Vo AA, Wechsler EA, Wang J et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am. J. Transplant.8(1), 144–149 (2008).
   PubMed Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med.359(3), 242–251 (2008).
   PubMed Web of Science ®Google Scholar
• Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET. Rituximab in highly sensitized kidney transplant recipients. Transplant. Proc.40(7), 2218–2221 (2008).
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am. J. Transplant.8(12), 2607–2617 (2008).
   PubMed Web of Science ®Google Scholar
• Haas M. The significance of C4d staining with minimal histologic abnormalities. Curr. Opin Organ Transplant.15(1), 21–27 (2010).
   PubMed Web of Science ®Google Scholar
• Stasi R, Cooper N, Del Poeta G et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood112(4), 1147–1150 (2008).
   PubMed Web of Science ®Google Scholar